Summary
B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood
cell responsible for fighting infections). Classic Follicular Lymphoma is a slow-growing
type of non-Hodgkin lymphoma. The purpose of this study is to assess the safety of
epcoritamab in adult participants in relapsed or refractory (R/R) diffuse large b-cell
lymphoma (DLBCL) who have received at least 1 prior line of systemic antilymphoma therapy
including at least 1 anti-CD20 monoclonal antibody-containing therapy or R/R classic
follicular lymphoma (cFL). Adverse events will be assessed.
Epcoritamab is an investigational drug being developed for the treatment of R/R DLBCL and
R/R cFL. Study doctors will assess participants in a monotherapy treatment arm of
epcoritamab. Participants will receive escalating doses of epcoritamab, until full dose
is achieved. Approximately 184 adult participants with R/R DLBCL and R/R cFL will be
enrolled in the study in approximately 80 sites in the United States of America.
Participants will receive escalating doses of subcutaneous epcoritamab, until full dose
is achieved, in 28-day cycles.
There may be higher treatment burden for participants in this trial compared to their
standard of care. Participants will attend regular visits during the study at an approved
institution (hospital or clinic). The effect of the treatment will be frequently checked
by medical assessments, blood tests, questionnaires and side effects.